Related Experiment Video
Updated: May 1, 2026
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy
Khaled Nassar1, Swaantje Grisanti2, Aysegul Tura2
1University of Luebeck, Department of Ophthalmology, Ratzeburger Allee 160, D-23538 Luebeck, Germany; Fayoum University, Department of Ophthalmology, 63514 Fayoum, Egypt.
Abstract:
This study evaluates the use of the TGF-β receptor 1 inhibitor LY-364947 (LY) to prevent proliferative vitreoretinopathy (PVR). For the in vitro experiments Human Tenon's Fibroblasts (HTFs) and retinal pigment epithelial (RPE) cells were treated with different concentrations of LY to determine HTF proliferation and RPE transdifferentiation. For in vivo testing 30 rabbits underwent a PVR trauma model. The animals received different concentrations of intravitreally injected LY, with or without vitrectomy. LY treatment reduced HTF proliferation and RPE transdifferentiation in vitro. In vivo intravitreal injection of LY prevented PVR development significantly. This positive effect was also present when LY injection was combined with vitrectomy. Intravitreal injection of LY prevented tractional retinal detachment in 14 out of 15 animals. In conclusion, treatment with the TGF-β receptor 1 inhibitor LY reduces HTF proliferation and RPE transdifferentiation in vitro and prevents proliferative vitreoretinopathy and subsequent tractional retinal detachment in vivo.
Insights
The TGF-β receptor 1 inhibitor LY-364947 (LY) effectively prevents proliferative vitreoretinopathy (PVR) and tractional retinal detachment. LY reduces cell proliferation and transdifferentiation in laboratory studies and animal models.
Area of Science:
- Ophthalmology
- Cell Biology
- Pharmacology
Background:
- Proliferative vitreoretinopathy (PVR) is a major cause of vision loss after retinal detachment surgery.
- Transforming growth factor-beta (TGF-β) signaling plays a critical role in the pathogenesis of PVR.
- Targeting TGF-β signaling pathways offers a potential therapeutic strategy for PVR.
Purpose of the Study:
- To evaluate the efficacy of LY-364947 (LY), a TGF-β receptor 1 inhibitor, in preventing PVR.
- To assess the effects of LY on human Tenon's fibroblasts (HTFs) proliferation and retinal pigment epithelial (RPE) cell transdifferentiation in vitro.
- To determine the in vivo efficacy of intravitreal LY injections in a rabbit model of PVR.
Main Methods:
- In vitro: HTFs and RPE cells were treated with varying concentrations of LY to assess proliferation and transdifferentiation.
- In vivo: A PVR trauma model was induced in 30 rabbits, followed by intravitreal injections of LY, with or without vitrectomy.
- Histological and functional assessments were performed to evaluate PVR development and retinal detachment.
Main Results:
- LY treatment significantly reduced HTF proliferation and RPE transdifferentiation in vitro.
- Intravitreal injection of LY demonstrated significant prevention of PVR development in the rabbit model.
- LY treatment, even when combined with vitrectomy, maintained its protective effect against PVR.
- LY injections prevented tractional retinal detachment in 14 out of 15 treated animals.
Conclusions:
- LY-364947 is a potent inhibitor of TGF-β receptor 1 signaling.
- LY effectively suppresses key cellular mechanisms involved in PVR pathogenesis.
- Intravitreal administration of LY shows significant therapeutic potential for preventing PVR and associated tractional retinal detachment.
Related Concept Videos
01:16TGF - β Signaling Pathway
01:27Diabetic Retinopathy
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...